

Index

Note: Page numbers of article titles are in **boldface** type.

A

Abacavir, adverse reactions to, in HIV infection, 203

ABCDs, to diagnose melanoma, 644, 671

Ablative lasers, for striae distensae, 74

Acanthosis nigricans

- cutaneous features of, 525
- in diabetes mellitus, 485
- with thyroid disease, 478

Acne scars, carbon dioxide laser therapy for, 83–84

Acquired ichthyosis, cutaneous features of, 525–526

Acquired perforating dermatosis

- in diabetes mellitus, 485–486
- in dialysis patients, 517

Acral-mucosal regions, melanoma of, 669–670, 673

Acrodermatitis enteropathica, with gastrointestinal disease, 538

Acropachy, thyroid, cutaneous features of, 476

Actinic cheilitis, laser therapy for, 153–154

Actinic dermatitis, with HIV infection, 203

Actinic keratoses, laser therapy for, 154–155

Activated charcoal, for pruritus, 462

Acyclovir

- for cytomegalovirus infections, 296
- for herpes simplex virus, 194, 256–259
- for herpes zoster virus, 275–276
- for human herpesvirus 6, 303
- for varicella, 273–274

Adhesion molecule expression, in cutaneous lupus erythematosus, 375

AIDS, Kaposi's sarcoma in, 308

Alexandrite lasers

for leg telangiectasias, 27–28

in hair removal, 140, 563–564

in tattoo removal, 49

parameters for, 5–6

Allergic reactions

- to insulin, for diabetes mellitus, 489
- to pigments, in tattoos, 170–171

AlloDerm, for chronic wounds, 361

Alopecia areata, with thyroid disease, 477

Alpha hydroxy acids, in skin preparation, for laser resurfacing, 116

Amelanotic melanoma, diagnosis of, 727–728

Amprenavir, adverse reactions to, in HIV infection, 203

Amputation, ray, for subungual melanoma, 690

Amyloidosis

- cutaneous and renal features of, 516, 527
- with cardiac disease, 506

Anemia, with thyroid disease, 477

Anesthesia

- in tattoo removal, by laser, 50
- regional. *See* Regional anesthesia.

Anesthetic agents, for pruritus, 467

Angiokeratoma corporis diffusum, with cardiac disease, 508

Angiomas

- cherry, laser therapy for, 13–14
- spider, laser therapy for, 12

Angiotensin-converting enzyme level, in sarcoidosis, 441

Animal-derived materials, for chronic wounds, 358–359

Anthranilates, in sunscreens, to prevent melanoma, 602–603

Antibiotics

- for infectious mononucleosis, adverse reactions to, 284
- for measles, 214

Antibody tests, for herpes simplex virus, 255

Antihistamines, for pruritus, 468

Antimalarials

- for cutaneous lupus erythematosus, 379
- for dermatomyositis, 400

Antimetabolites, for human papillomavirus, 321

Antiphospholipid antibody syndrome, cutaneous and renal features of, 515

Antiretroviral therapy, for HIV infection, 194

α_1 -Antitrypsin deficiency, panniculitis with, 431

Antiviral therapy

- for enterovirus infections, 221
- for herpes simplex virus, resistance to, 259

Apligraf, for chronic wounds, 362

Apogee System, in hair removal, 140

Argon lasers, continuous-wave. *See* Continuous-wave argon lasers.

Argon-pumped tunable dye lasers

- for facial telangiectasias, 1
- parameters for, 2

Arthralgias, with hepatitis C, 454

Arthritis

- parvovirus B19 infection and, 339
- with dermatomyositis, 397
- with pyoderma gangrenosum, 414

Aseptic meningitis, clinical features of, 219

Aspirin, for pruritus, 465

Ataxia-telangiectasia, cutaneous features of, 553–554

Atrophic scars, revision of, lasers in, 57, 60–62

Atypical measles, clinical features of, 210

Augmerosin, for melanoma, 711

Auricular melanoma, Mohs' micrographic surgery for, 706

Australia, melanoma in, 589, 591, 632, 636

Autoantibodies, in dermatomyositis, 397–398

Azelastin, for pruritus, 462

B

Bacillary angiomatosis, with HIV infection, 197

Bacterial infections

- and scleredema, 493
- avoidance of, in laser skin resurfacing, 118, 168
- in diabetes mellitus, 488
- varicella and, 269
- with HIV infection, 197–198

Bartonella infections, with HIV infection, 197

Basal cell nevus syndrome, cutaneous features of, 550–551

Bazex's syndrome

- cutaneous features of, 526
- with gastrointestinal disease, 543

Becker's nevus, laser therapy for, 42

Behcet's disease, with cardiac disease, 506

Benign dermal lesions, laser therapy for, 157–158

Benzophenones, in sunscreens, to prevent melanoma, 602

Bichloroacetic acid, for human papillomavirus, 320

Biochemotherapy, for melanoma, 710

Bioengineered human skin, for chronic wounds, 359–362

Biofeedback, in psychodermatology, 178

Biologic therapy, for pyoderma gangrenosum, 416

Biopsy, of subungual melanoma, 690

Birt-Hogg-Dubé syndrome, cutaneous and renal features of, 514

Bleaching agents, in skin preparation, for laser resurfacing, 116–117

Blood products, and hepatitis C, 237–238

Blue nevi

- diagnosis of, 729–730
- laser therapy for, 45

Botulinum toxin, **749–761**

- adverse effects of, 758
- contraindications to, 758
- for brow lift, 754–755
- for facial rhytides, 751–752
- for glabellar furrows, 752–753
- for horizontal forehead lines, 754–754
- for hyperhidrosis, 757
- for mentalis folds, 657
- for mouth frowns, 657
- for nasolabial folds, 657

for periocular crow's feet, 755–756
 for perioral rhytides, 657
 for platysmal rejuvenation, 756–757
 mechanism of action of, 749–750
 preparation of, 751
 response to, 758
 sources of, 749
 with brow lift, 757
 with chemical peels, 757
 with fillers, 757–758
 with laser skin surfacing, 757

Bourneville's disease, cutaneous and renal features of, 513–514

Bowel associated dermatosis-arthritis syndrome, cutaneous features of, 416–417, 537–538

Bowen's disease, laser therapy for, 155

Brain, magnetic resonance imaging of, for congenital melanocytic nevi, 614

Brain tumors, and pruritus, 466

Breslow thickness, to classify melanoma, 647–648

Brow lift
 botulinum toxin for, 754–755
 botulinum toxin with, 757

Bullae
 in diabetes mellitus, 484–485
 in dialysis patients, 517
 with thyroid disease, 477–478

Bullous pyoderma gangrenosum
 cutaneous features of, 413–414
 diagnosis of, 348

Burns, débridement of, carbon dioxide lasers in, 159

C

Café-au-lait macules
 in neurofibromatosis, 548
 laser therapy for, 41–42, 171–172

Calcifications, metastatic, in dialysis patients, 517–518

Calciphylaxis
 in dialysis patients, 518
 panniculitis with, 430

Calreticulin, in cutaneous lupus erythematosus, 375

Candidal infections
 with diabetes mellitus, 488
 with HIV infection, 199–200
 with thyroid disease, 478

Capsaicin, for pruritus, 462

Carbon dioxide lasers
 for epidermal and dermal lesions, 147–151, 153–159
 for human papillomavirus, 320
 for leg telangiectasias, 24
 for pigmented lesions, 38
 in scar revision, 60–62
 in skin resurfacing. *See* Skin resurfacing.
 in tattoo removal, 49–50

Carcinoid syndrome
 cutaneous features of, 524
 with cardiac disease, 506
 with gastrointestinal disease, 543

Cardiac disease, **503–511**
 clubbing in, 504
 coronary artery disease, 504–505
 earlobe creases in, 504
 hyperlipoproteinemia/xanthomas in, 504
 peripheral vascular disease in, 504–505
 cyanosis in, 503
 erythema in, 503–504
 flushing in, 503
 inherited diseases, 507–509
 Carney complex/myxoma, 509
 Ehler-Danlos syndrome, 507–508
 Fabry's disease, 508
 LEOPARD syndrome, 509
 Marfan's syndrome, 507
 Naxos disease, 509
 Noonan's syndrome, 508
 pseudoxanthoma elasticum, 508
 Werner syndrome, 508–509
 multisystem disease, 505–507
 amyloidosis, 506
 Behcet's disease, 506
 carcinoid syndrome, 506
 Degos' disease/malignant atrophic papulosis, 506
 hemochromatosis, 506–507
 infective endocarditis, 507
 Kawasaki's disease, 507
 relapsing polychondritis, 505–506
 scleroderma, 505
 systemic lupus erythematosus, 505

Cardiac features, of sarcoidosis, 438

Cardio-facio-cutaneous syndrome, versus Noonan's syndrome, 508

Carmustine, for melanoma, 709

Carney complex, with cardiac disease, 509

Carotenemia, in diabetes mellitus, 487

Cellular immune mechanisms, in cutaneous lupus erythematosus, 374–375

Cervical cancer, risk of, human papillomavirus in, 319–320

Cheilitis, actinic, laser therapy for, 153–154

Chemical cytodestruction, of human papillomavirus, 320

Chemical peels, botulinum toxin with, 757

Chemotherapy

- for Kaposi's sarcoma, 310
- for melanoma, **709–712**
 - combination, 709–710
 - immunomodulators with, 710
 - in limb perfusion, 710
 - new agents in, 711
 - single agents in, 709
- in limb perfusion, for recurrent melanoma, 688–689

Cherry angiomas, laser therapy for, 13–14

Chickenpox. *See* Varicella-zoster virus infection.

Chilblain cutaneous lupus erythematosus, diagnosis of, 377

Chloroquine

- for cutaneous lupus erythematosus, 379
- for dermatomyositis, 400

Cholestasis, and pruritus, 462–464

Cholesterol embolization syndrome, cutaneous and renal features of, 515

Cholestyramine, for pruritus, 463, 465

Chronic wounds, **357–363**

- animal-derived materials for, 358–359
- bioengineered human skin for, 359–362
- growth factors for, 357–358

Cidofovir

- for cytomegalovirus infections, 296
- for human papillomavirus, 321
- for management-resistant herpes simplex virus, 259

Cimetidine, for pruritus, 464–465

Cinnamates, in sunscreens, to prevent melanoma, 602

Cisplatin A, for melanoma, 709

Clonidine, preoperative, in laser therapy, 127

Clubbing

in cardiac disease, 504

in paraneoplastic dermatoses, 530

Coagulopathy, cutaneous features of, 529

Coccidioidomycosis, with HIV infection, 200

Codeine, for pruritus, 464

Composite Cultured Skin, for chronic wounds, 362

Compound melanocytic nevi, laser therapy for, 43

Computer-aided diagnosis, of melanoma, **735–747**

- confocal laser microscopy in, 744–745
- dermoscopic images in, 737–738
- for mole monitoring, 737
- hand-held probes in, 739–740
- machine vision in, 738–744
- teledermatology in, 736–737

Condoms, to prevent herpes simplex virus, 260

Condyloma acuminatum. *See* Human papillomavirus.

Confocal laser microscopy

- of amelanotic melanoma, 727–728
- of congenital melanocytic nevi, 613
- of melanoma, 744–745

Congenital melanocytic nevi, **607–616**, 662–663, 674–675

- classification of, 607
- diagnosis of, 610
- etiology of, 607–608
 - sunburns in, 613–614
- magnetic resonance imaging of brain for, 614
- management of, 612–613
- neurologic examination for, 614
- psychological burden of, 608
- risk factors for, 608, 610–612

Congenital rubella syndrome. *See* Rubella.

Conjunctivitis, hemorrhagic, clinical features of, 219

Connective tissue diseases, with thyroid disease, 478

Contact dermatitis, avoidance of, in skin resurfacing, 117–118

Continuous-wave argon lasers

- for facial telangiectasias, 10
- for hemangiomas, 6–7
- for leg telangiectasias, 21–22
- for pigmented lesions, 37–38
- parameters for, 1–2

Continuous-wave carbon dioxide lasers, for pigmented lesions, 38

Continuous-wave dye lasers, for leg telangiectasias, 21–22

Continuous-wave green light lasers, for pigmented lesions, 38

Continuous-wave Nd:YAG lasers, for leg telangiectasias, 22

Contour Er:YAG lasers, in skin resurfacing, 88, 91

Copper bromide lasers
for spider angiomas, 12
parameters for, 12

Copper vapor lasers
for facial telangiectasias, 11
for rosacea-associated telangiectasias and erythema, 12
for spider angiomas, 12
parameters for, 2

Coronary artery disease. *See* Cardiac disease.

Cowden disease, with gastrointestinal disease, 541–542

Cowpox, cutaneous features of, 345

Crohn's disease, cutaneous features of, 533

Cronkhite-Canada syndrome
cutaneous features of, 530
with gastrointestinal disease, 541

Crow's feet, botulinum toxin for, 755–756

Cryoglobulinemia
cutaneous and renal features of, 516, 530
with hepatitis C, 450–451

Cryotherapy, for human papillomavirus, 320

Cryptococcosis, with HIV infection, 200

Curettage and electrodesiccation, **569–577**
cosmetic results of, 573–574
cure rates in, 571–572
followed by excision, 572
histologic subtypes and, 573
historical aspects of, 569–570
rationale for, 574–576
recurrence after, 572–573
techniques for, 570–571
types of curettes in, 570

Cushing's syndrome, cutaneous features of, 524

Cutaneous field stimulation, for pruritus, 468

Cutaneous lupus erythematosus, **373–385**, 514–515
diagnosis of, 375–378
management of, 378–380
pathogenesis of, 373–375
cellular immune mechanisms in, 374–375
environment in, 374

genetic associations in, 373–374
humoral immune mechanisms in, 375

Cutaneous lymphomas, Epstein-Barr virus infection and, 286–287

Cutaneous mucinoses, diffuse. *See* Diffuse cutaneous mucinoses.

Cutaneous nephrology, **513–521**
amyloidosis, 516
antiphospholipid antibody syndrome, 515
Birt-Hogg-Dubé syndrome, 514
cholesterol embolization syndrome, 515
cryoglobulinemia, 516
dialysis patients, 516–518
acquired perforating dermatosis, 517
bullosis disorders, 517
calciphylaxis, 518
metastatic calcifications, 517–518
porphyria cutanea tarda, 517
pruritus, 516–517

end-stage renal disease, 516

Fabry's disease, 514

Henoch-Schönlein purpura, 515

hyperoxaluria, 515

lupus erythematosus, 514–515

nail-patella syndrome, 514

neurofibromatosis, 513

partial lipodystrophy, 514

polyarteritis nodosa, 515

pseudoxanthoma elasticum, 514

renal malignancies, 519

renal transplant patients, 518–519

systemic sclerosis, 515

tuberous sclerosis, 513–514

Wegener's granulomatosis, 515–516

Cutaneous T-cell lymphoma
Epstein-Barr virus infection and, 286–287
pruritus with, 465

CVD regimen, of chemotherapy, for melanoma, 710

Cyanosis, in cardiac disease, 503

Cyclosporine, for pyoderma gangrenosum, 353

Cyproheptadine, for pruritus, 464

Cytokines, in pruritus, 460

Cytomegalovirus infections, **291–299**
cutaneous features of, 293
diagnosis of, 293–295
management of, 295–296
natural history of, 292–293
virus binding and entry in, 292

virus structure in, 291
with HIV infection, 195

Cytophagic histiocytic panniculitis, cutaneous
features of, 425, 428

D

Dacarbazine, for melanoma, 709

Dapsone
for cutaneous lupus erythematosus, 379–380
for dermatomyositis, 400–401

Darier-Roussy sarcoid, panniculitis with, 430, 436

Deep-shave excision, of dysplastic nevi, 624

Degos' disease
with cardiac disease, 506
with gastrointestinal disease, 544–545

Delavirdine, adverse reactions to, in HIV
infection, 203

Demodicosis, with HIV infection, 201

Derma-K hybrid lasers, in skin resurfacing, 88, 91

Dermagraft, for chronic wounds, 361

Dermal lesions. *See* Epidermal and dermal lesions.

Dermal replacement, for chronic wounds, 361–362

Dermatitis
actinic, with HIV infection, 203
contact, avoidance of, in laser skin resurfacing,
117–118
seborrheic, with HIV infection, 202

Dermatitis herpetiformis, with gastrointestinal
disease, 538–539

Dermatologic complications, of herpes zoster
virus, 273

Dermatomyositis, **387–408**, 527–528
arthritis with, 397
classification of, 390–391
complications of, 398–400
dystrophic calcification, 399–400
internal malignancies, 398–399
cutaneous features of, 393–395
differential diagnosis of, 400
epidemiology of, 391–393
etiology and pathogenesis of, 402–403
historical aspects of, 387–388
laboratory features of, 397–397
management of, 400–401
nomenclature in, 388–390
parvovirus B19 infection and, 339
prognosis for, 401
pulmonary disease with, 395–397

Dermatophyte infections, with HIV infection, 199

Dermatoses
neutrophilic. *See* Neutrophilic dermatoses.
paraneoplastic. *See* Paraneoplastic dermatoses.

Dermatosis papulosa nigra, laser therapy for,
40–41

Dermopathy, in diabetes mellitus, 484

Dermoscopy
of amelanotic melanoma, 727
of congenital melanocytic nevi, 613
of melanoma, 622, **641–646**, 737–738
ABCDs in, 644
algorithm for, 644
checklist for, 645
historical aspects of, 641
Menzies method in, 644
terminology in, 641–642
to differentiate malignant from benign lesions,
642–644
to differentiate melanotic from nonmelanotic
lesions, 642

Desmoplastic melanoma
diagnosis of, 728–729
pathology of, 673

Diabetes mellitus, **483–492**
acanthosis nigricans in, 485
acquired perforating dermatosis in, 485–486
bacterial infections in, 488
bulae in, 484–485
dermopathy in, 484
diabetic foot in, 488–489
fungal infections in, 488
granuloma annulare in, 484
gustatory sweating in, 489
insulin for, cutaneous reactions to, 489
lichen planus in, 486
necrobiosis lipoidica in, 483–484
oral hypoglycemic agents for, cutaneous reactions
to, 489–490
pruritus in, 466
rubeosis faciei in, 487
scleredema in, 494
thick skin in, 486–487
xanthoma in, 487
yellow skin in, 487

Diabetic hand syndrome, glycemic control and, 487

Dialysis patients, cutaneous and renal findings in. *See*
Cutaneous nephrology.

Dibenzoylmethanes, in sunscreens, to prevent melanoma, 603

Diffuse cutaneous mucinosis, **493–501**
myxedema of hypothyroidism, 477, 498–499
reticular erythematous mucinosis, 497–498
scleredema, 493–495
scleromyxedema, 495–497

Diode lasers
for leg telangiectasias, 28–29
in hair removal, 140, 564–566
in skin resurfacing, 100, 106–108
parameters for, 3, 6

Diode-pumped vanadate lasers, for pigmented lesions, complications of, 172

DNA polymerase inhibitors, for cytomegalovirus infections, 295

Docetaxel, for melanoma, 709

Doxepin, for pruritus, 468

Drug reactions
with HIV infection, 203
with human herpesvirus 6, 308

Drug use, intravenous, and hepatitis C, 238

Dysplastic nevi, **617–628**, 681
biology of, 619–620
clinical features of, 620
genetics of, 617–618
histology of, 620–621
management of, 621–624
follow-up in, 621–622
genetic counseling in, 623
sunscreens in, 623
removal of, 623–624
scoring system for, 620

Dysport. *See* Botulinum toxin.

Dystrophic calcification, dermatomyositis and, 399–400

E

E2000 Laser, in hair removal, 139

Earlobe creases, in cardiac disease, 504

Eccrine hidradenitis, neutrophilic, cutaneous features of, 417

Eczema, with HIV infection, 201–202

Eczema herpeticum, herpes simplex virus and, 253

Ehlers-Danlos syndrome

with cardiac disease, 507–508
with gastrointestinal disease, 545

Encephalitis, measles and, 211

End-stage renal disease, cutaneous and renal features of, 516

Endocarditis, infective, with cardiac disease, 507

Endocrine dysfunction
and pruritus, 465–466
in ataxia-telangiectasia, 554

Endocrine features, of sarcoidosis, 438

Endocrinopathies, with thyroid disease, 478

Enterovirus infections, **217–223**
clinical features of, 218–220
diagnosis of, 220
epidemiology of, 217–218
management of, 220–221
pathogenesis of, 217

Environmental factors
in cutaneous lupus erythematosus, 374
in sarcoidosis, 440

Enzyme linked immunosorbent assay, for measles, 211

Eosinophilia myalgia syndrome, cutaneous features of, 423–424

Eosinophilic fasciitis, cutaneous features of, 422–423

Eosinophilic folliculitis, with HIV infection, 202–203

Ephelides, laser therapy for, 41

Epidermal and dermal lesions, laser therapy for, 39–40, 44, **147–164**
actinic cheilitis, 153–154
actinic keratoses, 154–155
benign growths, 157–158
carbon dioxide lasers in, 147–151, 153–159
condyloma acuminatum, 154
Er:YAG lasers in, 148–149
excisional, 158–159
inflammatory conditions, 155
laser-tissue interactions in, 147–148
nevi. *See* Nevi.
pulsed dye lasers in, 151–152
rhinophyma, 155–157
safety of, 148–149
seborrheic keratoses, 40–41, 155
skin cancer, 155
skin resurfacing in, 149–150

technique for, 149–150
verrucae, 150–152
wound care in, 150

Epidermal nevus syndrome, cutaneous features of, 551–552

Epidermodysplasia verruciformis, human papillomavirus and, 318–319

Epilaser, in hair removal, 139

EpiPulse Ruby lasers, in hair removal, 139

Epithelioid cell melanoma, of trunk and proximal extremities, 672

Epitouch lasers, in hair removal, 140

Epothilone, for melanoma, 711

Epstein-Barr virus infection, 283–289
and cutaneous lymphomas, 286–287
and infectious mononucleosis, 283–285
and oral hairy leukoplakia, 285–286
historical aspects of, 283
with HIV infection, 195

Erbium glass lasers, in skin resurfacing, 104–105

Erbium lasers, in tattoo removal, 49–50

Eruptive xanthomas, in cardiac disease, 504

Er:YAG lasers
for epidermal and dermal lesions, 148–149
in scar revision, 61–62
in skin resurfacing. *See Skin resurfacing.*

Erythema
in cardiac disease, 503–504
laser skin resurfacing and, 93, 168
necrolytic migratory, cutaneous features of, 523–524

Erythema gyratum repens, cutaneous features of, 526

Erythema infectiosum, parvovirus B19 infection and, 334–335

Erythema multiforme, herpes simplex virus and, 253

Erythema nodosum
cutaneous features of, 421–422
in sarcoidosis, 437
infectious mononucleosis and, 284

Erythoplasia of Queyrat, laser therapy for, 155

Erythroderma, cutaneous features of, 529

Erythropoietin, for pruritus, 462

E-selectin, in dermatomyositis, 398

Exanthema subitum, human herpesvirus 6 and, 303

Extracorporeal plasmapheresis, for pruritus, 463

Extremities, proximal, melanoma of, 664–666, 672–673

Eyelids, photodamaged, laser therapy for, 91

F

Fabry's disease
cutaneous and renal features of, 514
with cardiac disease, 508

Facial aesthetics, botulinum toxin in. *See Botulinum toxin.*

Facial blocks, in laser therapy, 128–130
complications of, 130
inadequate, 132

Facial melanoma, surgery for, 691–692

Facial rhytides, botulinum toxin for, 751–752

Facial telangiectasias, laser therapy for, 10–11
complications of, 173

Famciclovir
for herpes simplex virus, 256–259
for herpes zoster virus, 275

Familial atypical mole and melanoma syndrome, biology of, 619

FAS, in cutaneous lupus erythematosus, 375

Fibromyalgia, with dermatomyositis, 395

Fibrosis, pulmonary, with dermatomyositis, 396

Fifth disease, parvovirus B19 infection and, 334–335

Flashlamp-pumped pulse dye lasers. *See Pulsed dye lasers.*

5-Fluorouracil, for human papillomavirus, 321

Flushing, in cardiac disease, 503

Folliculitis
eosinophilic, with HIV infection, 202–203
with HIV infection, 197

Fomivirsen, for cytomegalovirus infections, 296

Fong's syndrome, cutaneous and renal features of, 514

Forehead lines, botulinum toxin for, 753–754

Foscarnet
adverse reactions to, in HIV infection, 203

for cytomegalovirus infections, 295–296
for management-resistant herpes simplex virus, 259
for management-resistant herpes zoster virus, 276

Fungal infections
in diabetes mellitus, 488
with HIV infection, 199–200

G

G-319, for melanoma, 711

Ganciclovir
for cytomegalovirus infections, 295
for human herpesvirus 6, 303

Gardner's syndrome, with gastrointestinal disease, 541

Gastrointestinal disease, **533–546**
acrodermatitis enteropathica with, 538
Bazex's syndrome with, 543
bowel associated dermatosis-arthritis syndrome with, 537–538
carcinoid syndrome with, 543
Cowden disease with, 541–542
Crohn's disease, 533
Cronkhite-Canada syndrome with, 541
cutaneous eruptions due to malabsorption with, 538
Degos' disease with, 544–545
dermatitis herpetiformis with, 538–539
Ehlers-Danlos syndrome with, 545
Gardner's syndrome with, 541
glucagonoma with, 543
hereditary hemorrhagic telangiectasia with, 544
Howell-Evans syndrome with, 542
Kaposi's sarcoma with, 544
lichen planus with, 539
Muir-Torre syndrome with, 542
multiple endocrine neoplasia with, 542
necrotizing angiitis with, 544
pancreatic panniculitis with, 539
Peutz-Jeghers syndrome with, 542
Plummer-Vinson syndrome with, 542–543
porphyria cutanea tarda with, 539
pseudoxanthoma elasticum with, 545
pustular reactions in, 538
pyoderma gangrenosum with, 533–536
Sweet's syndrome with, 536–537
ulcerative colitis, 533

Genital ulcers, infectious mononucleosis and, 284–285

Genital warts. *See* Human papillomavirus.

Gentlelase, in hair removal, 140

German measles. *See* Rubella.

Gingival telangiectasia, in dermatomyositis, 394

Glabellar furrows, botulinum toxin for, 752–753

“Gloves and socks” syndrome, parvovirus B19 infection and, 335–336

Glucagonoma, with gastrointestinal disease, 543

Glycolic acid, in skin preparation, for laser resurfacing, 116

Gorlin syndrome, cutaneous features of, 550–551

Granulocyte-macrophage colony stimulating factor, for chronic wounds, 358

Granuloma annulare, in diabetes mellitus, 484

Granulomas, pyogenic, laser therapy for, 12–13

Graves' disease
and pruritus, 465
cutaneous features of, 475–476

Growth factors, for chronic wounds, 357–358

Gustatory sweating, in diabetes mellitus, 489

H

Hair changes, in hypothyroidism, 477

Hair removal
lasers in, **135–146, 561–567**
alexandrite lasers, 140, 563–564
complication of, 143, 171
diode lasers, 140, 564–566
intense pulsed nonlaser light source, 566
long-pulsed Nd:YAG lasers, 141
microwave delivery systems in, 142
Nd:YAG lasers, 566–567
patient expectations in, 144
postoperative care for, 143
preoperative preparation for, 142
pulsed, noncoherent broadband light sources, 141–142
Q-switched Nd:YAG lasers, 137, 141
results of, 144
ruby lasers, 139–140, 562–563
safety of, 143–144
Softlight System, 137–139
technique for, 142–143
technology in, 135–138
terminology in, 138–139
photodynamic therapy in, 138

Hand-foot-mouth syndrome, clinical features of, 219

Head and neck, melanoma of, 666–669, 673

Healthcare workers

- hepatitis B in, 234
- hepatitis C in, 238

Hemangiomas, laser therapy for, 6–8

- complications of, 173

Hematologic complications, of varicella, 270

Hematopoietic diseases, and pruritus, 464–465

Hemochromatosis, with cardiac disease, 506–507

Hemorrhagic conjunctivitis, clinical features of, 219

Henoch-Schönlein purpura, cutaneous and renal features of, 515

Hepatic complications, of varicella, 270

Hepatic features, of sarcoidosis, 438

Hepatitis, viral. *See* Viral hepatitis.

Hepatitis B immunoglobulin, to prevent hepatitis B, 236–237

Hepatitis C, 449–458

- arthralgias in, 454
- co-infections with, 455
- cryoglobulinemia in, 450–451
- cutaneous features of, 450–454
- diagnosis of, 454
- etiology of, 449–450
- lichen planus in, 452
- lymphoproliferative disorders in, 454
- management of, 454–455
- pathogenesis of, 450
- polyarteritis nodosa in, 453
- porphyria cutanea tarda in, 451–452
- pruritus in, 452–453
- pyoderma gangrenosum in, 453
- Sjögren's syndrome in, 452
- systemic lupus erythematosus in, 453
- urticaria in, 452
- vitiligo in, 453

Hepatobiliary disease, and pruritus, 462–464

Herpangina, clinical features of, 219

Herpes genitalis. *See* Herpes simplex virus.

Herpes labialis. *See* Herpes simplex virus.

Herpes simplex virus, 249–266. *See also* Herpesviruses.

- clinical features of, 251–254
- herpes genitalis, 251–252
- herpes labialis, 251

in immunocompromised patients, 253–254

- in neonates, 253

diagnosis of, 254–255

- in pregnancy, 255

epidemiology of, 249–250

- herpes genitalis, 249
- herpes labialis, 249

etiology of, 249–250

- herpes genitalis, 249
- herpes labialis, 249

management of, 256–259

- herpes genitalis, 258
- herpes labialis, 257–258

in immunocompromised patients, 259

- in pregnancy, 258–259
- resistance to, 259

pathogenesis of, 250–251

- herpes genitalis, 250–251
- herpes labialis, 251

pathology of, 256

prevention of, 259–261

transmission of, 249–250

- herpes genitalis, 249–250
- in laser skin resurfacing, 168

with HIV infection, 250

Herpes zoster virus. *See* Varicella-zoster virus infection.

Herpesviruses, 302–306, 307–314. *See also* Herpes simplex virus.

- human herpesvirus 6, 301–303
 - biology of, 302
 - diagnosis of, 303
 - disease associations with, 303
 - epidemiology of, 302
 - management of, 303
- human herpesvirus 7, 303–305
 - biology of, 304
 - diagnosis of, 305
 - disease associations with, 304–305
 - epidemiology of, 304
 - management of, 305
- human herpesvirus 8, 307–314
 - and Kaposi's sarcoma, 307–310
 - clinical variants of, 307–308
 - epidemiology of, 309–310
 - management of, 310
 - molecular biology of, 309
 - and multicentric Castleman's disease, 310–311
 - and primary effusion lymphoma, 311
 - with HIV infection, 194–196

Herpetic whitlow, clinical features of, 253

Hidradenitis, neutrophilic eccrine, cutaneous features of, 417

Highly active antiretroviral therapy, for HIV infection, 194

Histamine, in pruritus, 459

Histoplasmosis, with HIV infection, 200

HIV infection, cutaneous features of, 193–208
 adverse drug reactions, 203
 bacillary angiomatosis, 197
 candidal infection, 199–200
 coccidioidomycosis, 200
 cryptococcosis, 200
 cytomegalovirus, 195
 demodicosis, 201
 dermatophyte infection, 199
 eosinophilic folliculitis, 202–203
 herpes simplex virus, 194
 herpes zoster virus, 271
 herpesviruses, 194, 250
 histoplasmosis, 200
 human papillomavirus, 196, 319
 Kaposi's sarcoma, 195–196
 molluscum contagiosum, 196–197, 344
 mycobacterial infection, 197–198
 oral hairy leukoplakia, 195
 photosensitivity disorders, 203–204
 primary HIV infection, 193–194
 psoriasis and Reiter's syndrome, 202
 scabies, 201
 seborrheic dermatitis, 202
 staphylococcal infection and folliculitis, 197
 syphilis, 198
 varicella, 269
 varicella-zoster virus, 194–195
 xerosis and eczema, 201–202

HLA antigens, in vaccines, for melanoma, 718–719

HMB-45, in Mohs' micrographic surgery, for melanoma, 705

Hodgkin's disease, pruritus with, 465

Holster sign, in dermatomyositis, 394

Human papillomavirus, 315–331
 and epidermodysplasia verruciformis, 318–319
 classification of, 317
 epidemiology of, 319–320
 genital mucosal features of, 319
 in immunocompromised patients, 319
 laser therapy for, 153
 management of, 3202–323

nongenital cutaneous features of, 317–318
 pathogenesis of, 316–317
 prevention of, 323–324
 virus structure in, 315–316
 with HIV infection, 196

Humoral immune mechanisms, in cutaneous lupus erythematosus, 375

Hydroquinone, in skin preparation, for laser resurfacing, 116–117

Hydroxychloroquine
 for cutaneous lupus erythematosus, 379
 for dermatomyositis, 400

Hyperhidrosis, botulinum toxin for, 757

Hyperlipoproteinemia, in cardiac disease, 504

Hyperoxaluria, cutaneous and renal features of, 515

Hyperpigmentation
 laser hair removal and, 143
 laser skin resurfacing and, 93, 166
 laser tattoo removal and, 48
 postinflammatory, laser therapy for, 42

Hypertension, regional anesthesia and, 132–133

Hyperthyroidism
 and pruritus, 465
 cutaneous features of, 474–475

Hypertrichosis lanuginosa acquisita, cutaneous features of, 525

Hypertrophic cutaneous lupus erythematosus, diagnosis of, 376–377

Hypertrophic scars, revision of, lasers in, 56, 59–60

Hypnosis, in psychodermatology, 178–179

Hypoglycemic agents, for diabetes mellitus, cutaneous reactions to, 489–490

Hypopigmentation
 laser hair removal and, 143
 laser skin resurfacing and, 93–94, 166, 168
 laser tattoo removal and, 48

Hypothyroidism
 and pruritus, 465–466
 cutaneous features of, 476–477
 myxedema of, 477, 498–499

I

Ichthyosis, acquired, cutaneous features of, 525–526

Idiopathic inflammatory myopathies.
See Dermatomyositis.

Idiopathic lobular panniculitis, cutaneous features of, 425

Imiquimod, for human papillomavirus, 322

Immunocompromised patients

- cytomegalovirus infections in, 293
- herpes simplex virus in, 250
 - clinical features of, 253–254
 - management of, 259
- herpes zoster virus in, 271
- human papillomavirus in, 319
- measles in, 210
- varicella in, 268–269

Immunomodulators

- for melanoma, 710
- for recurrent melanoma, 689–690

Immunosuppressive therapy

- for cutaneous lupus erythematosus, 379
- for pyoderma gangrenosum, 416

Immunotherapy, with surgery, for melanoma, 686–687

In situ hybridization technique, for cytomegalovirus infections, 294

Incontinentia pigmenti, cutaneous features of, 554–555

Indinavir, adverse reactions to, in HIV infection, 203

Infections

- and sarcoidosis, 440
- bacterial, avoidance of, in laser skin resurfacing, 118, 168
- in diabetes mellitus, 488
- panniculitis with, 430–431

Infectious mononucleosis, Epstein-Barr virus infection and, 283–285

Inflammatory bowel disease, cutaneous features of, 533

Inflammatory disorders, laser therapy for, 155

Inflammatory response, in melanoma, 652

Infra-orbital nerve blocks, in laser therapy, 130

Infrared lasers, for striae distensae, 69

Insulin, for diabetes mellitus, cutaneous reactions to, 489

Integra Dermal Regeneration Template, for chronic wounds, 361

Intense pulsed light source

- for leg telangiectasias, 14, 31–33

in hair removal. *See Hair removal*

in skin resurfacing, 101–102

parameters for, 5

Interferons

- for hepatitis B, 237
- for hepatitis C, 454
- for human papillomavirus, 321–322
- for lichen planus, 242
- for melanoma, 710
 - with surgery, 686
- for mixed cryoglobulinemia, 240
- for porphyria cutanea tarda, 241
- for pruritus, 465

Interleukins, for melanoma, 710

Interstitial pneumonitis, with dermatomyositis, 396–397

Intratumoral therapy, for recurrent melanoma, 689–690

Intravenous drug use, and hepatitis C, 238

Intravenous immunoglobulin, for parvovirus B19 infection, 340

Iron supplementation, for pruritus, 465

J

Jaw cysts, in basal cell nevus syndrome, 551

Junctional melanocytic nevi, laser therapy for, 43

K

Kaposi's sarcoma

- human herpesvirus 8 and. *See Herpesviruses*.
- with gastrointestinal disease, 544
- with HIV infection, 195–196

Kaposi's varicelliform eruption, herpes simplex virus and, 253

Kawasaki's disease, with cardiac disease, 507

Keloids, revision of, lasers in, 56–57, 59–60, 159

Keratinocyte-derived growth factor, for chronic wounds, 358

Keratoses

- actinic, laser therapy for, 154–155
- seborrheic, laser therapy for, 40–41, 155

Ketamine, intraoperative, in laser therapy, 128

Ketorolac, postoperative, in laser therapy, 133

KL-6, in dermatomyositis, 398

Krypton lasers
for pigmented lesions, complications of, 172
parameters for, 2

KTP lasers
for leg telangiectasias, 24
for rosacea-associated telangiectasias and erythema, 12
in skin resurfacing, 102–103
parameters for, 2–3

L

Lactate dehydrogenase, in metastatic melanoma, 649

Lamivudine, for hepatitis B, 237

Laser therapy. *See also* Lasers.
complications of, 165–176
for cutaneous lupus erythematosus, 378–379
for epidermal and dermal lesions. *See* Epidermal and dermal lesions.
for human papillomavirus, 320
for leg telangiectasias. *See* Leg telangiectasias.
for pigmented lesions. *See* Pigmented lesions.
for vascular lesions. *See* Vascular lesions.
patient selection for, 165
regional anesthesia in. *See* Regional anesthesia.

Lasers. *See also* Laser therapy.
in hair removal. *See* Hair removal.
in scar revision. *See* Scar revision.
in skin resurfacing. *See* Skin resurfacing.
in tattoo removal. *See* Tattoo removal.

Leg telangiectasias
diagnosis of, 19–20
laser therapy for, 14, 19–36
carbon dioxide lasers in, 24
complications of, 173–174
continuous-wave argon and dye lasers in, 21–22
continuous-wave Nd:YAG lasers in, 22
cooling in, 33–34
diode lasers in, 28–29
indications for, 34
intense pulsed light source in, 14, 31–33
KTP lasers in, 24
long-pulsed alexandrite lasers in, 27–28
long-pulsed dye lasers in, 14, 26–27
long-pulsed Nd:YAG lasers in, 29–30
parameters for, 21
pulsed dye lasers in, 14, 24, 26
ultra-long pulsed dye lasers in, 14

Lentigines, laser therapy for, complications of, 172

Lentigo maligna
histogenesis of, 659
laser therapy for, 155
Mohs' micrographic surgery for, 705
radiation therapy for, 714

Lentigo simplex, laser therapy for, 40

LEOPARD syndrome, with cardiac disease, 509

Leukemia, panniculitis with, 430

Leukine, for chronic wounds, 358

Libman-Sachs endocarditis, in systemic lupus erythematosus, 505

Lichen myxedematosus, cutaneous features of, 495–497

Lichen planus
hepatitis C and, 241–242
with diabetes mellitus, 486
with gastrointestinal disease, 539
with hepatitis C, 452

Limb perfusion
for melanoma, 710
for recurrent melanoma, 688–689

Lipoatrophy, in diabetes mellitus, insulin and, 489

Lipodermatosclerosis, cutaneous features of, 422

Lipodystrophy
in dermatomyositis, 394
partial, cutaneous and renal features of, 514

Lipohypertrophy, in diabetes mellitus, insulin and, 489

Lomustine, for melanoma, 709

Long-pulsed alexandrite lasers, for leg telangiectasias, 27–28

Long-pulsed dye lasers
for leg telangiectasias, 14, 26–27
for pigmented lesions, 39
parameters for, 4

Long-pulsed Er:YAG lasers, in scar revision, 61–62

Long-pulsed KTP lasers, in skin resurfacing, 102–103

Long-pulsed Nd:YAG lasers
for leg telangiectasias, 29–30
in hair removal, 141
in skin resurfacing, 102–103

Loop electrosurgical excision, for human papillomavirus, 320

Lupus band test, for cutaneous lupus erythematosus, 376

Lupus erythematosus
cutaneous. *See* Cutaneous lupus erythematosus.
renal features of, 514-515
systemic, with cardiac disease, 505
versus reticular erythematous mucinosis, 497
with hepatitis C, 453
with panniculitis, 430

Lupus panniculitis, diagnosis of, 377

Lupus pernio, in sarcoidosis, 435-436

Lymph nodes, in melanoma, 684-686

Lymphangioma circumscriptum, laser therapy for, 157-158

Lymphomas
cutaneous T-cell
Epstein-Barr virus infection and, 286-287
pruritus with, 465
panniculitis with, 430
primary effusion, human herpesvirus 8 and, 311

Lymphoproliferative disorders, with hepatitis C, 454

M

Macrometastases, from melanoma, 648

Magnetic resonance imaging
of brain, for congenital melanocytic nevi, 614
of dystrophic calcification, in dermatomyositis, 399-400

Magnetic resonance spectroscopy, of muscle abnormalities, in dermatomyositis, 394-395

Malabsorption, cutaneous eruptions due to, 538

Malignancies
and pruritus, 466
internal, dermatomyositis and, 398-399, 527
renal, cutaneous and renal features of, 519
with pyoderma gangrenosum, 414

Malignant atrophic papulosis, with cardiac disease, 506

Malignant pyoderma, cutaneous features of, 413

Malignant skin tumors, human papillomavirus and, 318

Marfan's syndrome, with cardiac disease, 507

Mastocytosis, pruritus with, 465

McCune-Albright syndrome, with thyroid disease, 478

Measles, 209-215
clinical features of, 210
complications of, 210-211
diagnosis of, 211
epidemiology of, 211-212
immune response in, 209-210
in immunocompromised patients, 210
laboratory findings in, 211
management of, 214
mumps, rubella vaccine, complications of, 229
pathogenesis of, 209-210
prevention of, 212-214

Mechanic's hand lesion, in dermatomyositis, 393

Mel-5, in Mohs' micrographic surgery, for melanoma, 705

MelaFind probe, to diagnose melanoma, 739-740

Melan-A antigen, in Mohs' micrographic surgery, for melanoma, 705

Melanocytic nevi, congenital. *See* Congenital melanocytic nevi.

Melanoma
biology of, 701
biopsy of, 677-680, 682
decision making in, 677
excisional, 678-679
incisional, 679
saucerization in, 679
terminology in, 678
chemotherapy for. *See* Chemotherapy.
dermoscopy of. *See* Dermoscopy.
diagnosis of, 622, 682
computer-aided. *See* Computer-aided diagnosis.
frozen sections in, 703
epidemiology of, 681-682
incidence of, 589-595
artifacts in, 593
body site and, 592-593
geographic location in, 589
in United States, 591-592
skin color and, 591
metastatic work-up in, 683-684
pathology of, 659-676
ABCs in, 671
clinicopathologic features, 659
desmoplastic and neurotropic melanomas, 673
histogenetic subtypes, 659-661
histologic reporting in, 673-674
in acral-mucosal regions, 669-670
in dermis, 671-672

of acral-mucosal regions, 673
of head and neck, 673
of trunk and proximal extremities, 672–673
in head and neck, 666–669
in trunk and proximal extremities, 664–666
mitotic rate, 674
nodular melanoma, 672
precursor lesions, 662
satellite lesions, 674
thickness, 674, 682–683
tumor progression model, 663
ulceration, 674
vascular invasion, 674
prevention of
sunblocks in, 601–602
sunscreens in. *See* Sunscreens.
prognostic factors for, 647–658
age, 651–652
anatomic site, 651
cell type, 652
gender, 651
growth patterns, 652
inflammatory response, 652
level of dermal invasion, 650–651
markers as, 653
mitotic rate, 652
regression, 652
staging, 649–650, 682–683
TNM system, 647–649
M classification, 649
N classification, 648–649
T classification, 647–648
vascular invasion, 652–653
radiation therapy for, 713–716
palliative, 713–714
potentially curable, 714–715
risk factors for, 597–600, 681–682
gender, 632
genetics, 597–599
place of birth, 599
previous melanoma, 599
socioeconomic status, 599, 632
screening for, 629–640
criteria for, 630–631
dermatologists in, 632–634
guidelines for, 631
in high-risk populations, 631–632
in primary care setting, 634
physician and nurse training in, 637
rationale for, 629–630
surgery for, 681–699
adjuvant immunotherapy with, 686–687
excisional margins in, 684, 701–702
follow-up of, 687
for clinically negative lymph nodes, 684–686
for clinically positive lymph nodes, 686
for facial melanoma, 691–692
for lesions of uncertain diagnosis, 692–693
for local recurrence, 687–688
for plantar melanoma, 691
for subungual melanoma, 690–691
in pregnancy, 693–694
Mohs' micrographic. *See* Mohs' micrographic surgery.
surveillance of, total body photography in, 623
unifying concept for, 660–661
unusual types of, 727–733
amelanotic, 727–728
desmoplastic, 728–729
malignant blue nevi, 729–730
nevus of Ota-associated, 730–731
subungual, 731
vaccines for. *See* Vaccines.
Melasma, laser therapy for, 42
complications of, 172
Melastatin, as marker, for melanoma, 653
Meningitis, aseptic, clinical features of, 219
Menkes disease, cutaneous features of, 555
Mental nerve blocks, in laser therapy, 130
Mentalis folds, botulinum toxin for, 756
Menzies method, to diagnose melanoma, 644
Metabolic disorders, and pruritus, 465–466
Metastatic calcifications, in dialysis patients, 517–518
Metastatic disease, cutaneous, from thyroid malignancies, 474
Microdermabrasion, with laser therapy, for striae distensae, 74–75
Micrometastases, from melanoma, 69, 648
Microphthalmia transcription factor, as marker for desmoplastic melanoma, 729
Microwave delivery system, in hair removal, 142
Milker's nodules, cutaneous features of, 345
Mitotic rate, in melanoma, 652, 674
Mixed cryoglobulinemia, hepatitis C and, 239–240
Mohs' micrographic surgery
for lentigo maligna, 705
for melanoma, 701–708

excisional margins in, 704
histologic stains in, 704–705
historical aspects of, 703
of ears, 706
of feet, 706
of nails, 705–706
of nose, 706
of oral cavity, 706
paraffin sections in, 705
periorbital, 706

Mole monitoring, in melanoma, 737

Molecular markers, for melanoma, 653

Molluscum contagiosum
cutaneous features of, 343–344
with HIV infection, 196–197

Monkeypox, cutaneous features of, 345

Monoclonal gammopathy, and scleredema, 493–494

Mononucleosis, infectious, Epstein-Barr virus
infection and, 283–285

Mouth frowns, botulinum toxin for, 756

Mucinoses, diffuse cutaneous. *See* Diffuse
cutaneous mucinoses.

Muir-Torre syndrome, with gastrointestinal
disease, 542

Multicentric Castleman's disease, human herpesvirus
8 and, 310–311

Multiple endocrine neoplasia
and pruritus, 466
cutaneous metastases from, 474
with gastrointestinal disease, 542
with thyroid disease, 478

Multiple sclerosis, and pruritus, 466

Muscle abnormalities, in dermatomyositis, 394–395

Musculoskeletal features, of sarcoidosis, 438

Mycobacteria
and sarcoidosis, 440
with HIV infection, 197–198

Mycosis fungoides, pruritus with, 465

Myobloc. *See* Botulinum toxin.

Myocarditis, enterovirus infections and, 219–220

Myopathies, idiopathic inflammatory.
See Dermatomyositis.

Myxedema, with hypothyroidism, 477, 498–499

Myxoma, with cardiac disease, 509

N

Nail-patella syndrome, cutaneous and renal features
of, 514

Nalmefene, for pruritus, 464

Naloxone, for pruritus, 464

Naltrexone, for pruritus, 462, 464, 468

Nasal melanoma, Mohs' micrographic surgery
for, 706

Nasolabial folds, botulinum toxin for, 756

Nausea and vomiting, regional anesthesia and, 132

Naxos disease, with cardiac disease, 509

Nd:YAG lasers
for hemangiomas, 8
for leg telangiectasias, 22
for pigmented lesions, complications of, 172
in hair removal, 137, 141, 566–567
in skin resurfacing, 99–100, 102–103, 105–106
complications of, 169
in tattoo removal, 49

Necrobiosis lipoidica, in diabetes mellitus,
483–484

Necrolytic migratory erythema, cutaneous features of,
523–524

Necrotizing angiitis, with gastrointestinal
disease, 544

Neonatal panniculitis, cutaneous features of, 429

Nephrology, cutaneous. *See* Cutaneous nephrology.

Nerve blocks, facial. *See* Facial blocks.

Neuralgia, postherpetic, clinical features of, 272

Neurocutaneous disorders, 547–560
ataxia-telangiectasia, 553–554
basal cell nevus syndrome, 550–551
epidermal nevus syndrome, 551–552
incontinentia pigmenti, 554–555
Menkes disease, 555
neurofibromatosis, 547–549
POEMS syndrome, 555–556
tuberous sclerosis, 549–550
xeroderma pigmentosum, 552–553

Neurofibromatosis, cutaneous and renal features of,
513, 547–549

Neurologic complications
of herpes zoster virus, 272
of measles, 211
of sarcoidosis, 438

of varicella, 269
of xeroderma pigmentosum, 553

Neurologic disorders, and pruritus, 466

Neurologic examinations, for congenital melanocytic nevi, 614

Neuropeptides, in pruritus, 460

Neurotropic melanoma, pathology of, 673

Neutrophilic dermatoses, 409-419
bowel associated dermatosis-arthritis syndrome, 416-417
neutrophilic eccrine hidradenitis, 417
pyoderma gangrenosum, 347-355, 412-416
 atypical or bullous, 413-414
 cutaneous features of, 412
 diagnosis of, 347-349, 414-415
 differential diagnosis of, 415
 diseases associated with, 414
 etiology and pathogenesis of, 414
 histopathology of, 414
 malignant, 413
 management of, 351-354, 415-416
 systemic, 352-353
 topical and intralesional, 351-352
 peristomal, 412-413
 stabilizing patient with, 350
 systemic disease with, 349-350
 vulvar, 413
 with hepatitis C, 453
 with inflammatory bowel disease, 533-536
 wound care in, 350-351

rheumatoid, 416

Sweet's syndrome, 409-412, 528
 diagnosis of, 411
 diseases associated with, 410-411
 epidemiology of, 409
 histopathology of, 409-410
 laboratory findings in, 409
 management of, 411-412
 pathogenesis of, 411
 with gastrointestinal disease, 536-537
 with thyroid disease, 478-479

Nevi
dysplastic. *See* Dysplastic nevi.
laser therapy for
 complications of, 172
 congenital, 43-44
 epidermal, 155
 nevocellular, 42-43
 sebaceous, 157

melanocytic. *See* Congenital melanocytic nevi.

Nevi spilus, laser therapy for, 42

Nevirapine, adverse reactions to, in HIV infection, 203

Nevus of Ito, laser therapy for, 44-45

Nevus of Ota
 and melanoma, 730-731
 laser therapy for, 44-45

New Zealand, melanoma in, 589, 591

Nicotine patches, for pyoderma gangrenosum, 352

Nitrosoureas, for melanoma, 709

Nodular vasculitis, panniculitis with, 431

Nonablative lasers
 for striae distensae, 68-69
 in skin resurfacing. *See* Skin resurfacing.

Nonlaser light sources, in hair removal, 566

Nonmelanoma skin cancers, curettage and electrodesiccation for. *See* Curettage and electrodesiccation.

Nonnucleoside reverse transcriptase inhibitors, adverse reactions to, in HIV infection, 203

Nonpolio enterovirus infections
 clinical features of, 219
 epidemiology of, 218

Noonan's syndrome, with cardiac disease, 508

Nucleoside analogues, for hepatitis B, 237

Nucleoside reverse transcriptase inhibitors, adverse reactions to, in HIV infection, 203

O

Oasis grafts, for chronic wounds, 358-359

Occlusive dressings, for chronic wounds, 357

Ocular abnormalities
 in ataxia-telangiectasia, 553
 in herpes zoster virus, 273
 in sarcoidosis, 437
 in xeroderma pigmentosum, 553

Odontogenic keratocysts, in basal cell nevus syndrome, 551

Ondansetron, for pruritus, 462, 468

Opioid antagonists, for pruritus, 464, 468

Opioids, in pruritus, 460

Oral hairy leukoplakia
 Epstein-Barr virus infection and, 285-286
 with HIV infection, 195

Oral melanoma, Mohs' micrographic surgery for, 706
Orf, cutaneous features of, 345
Osler-Weber-Rendu disease, with gastrointestinal disease, 544
Osteo-onychodysplasia, cutaneous and renal features of, 514

P

PABA, in sunscreens, to prevent melanoma, 602, 604
Paclitaxel, for melanoma, 709
Palmar pits, in basal cell nevus syndrome, 550–551
Pancreatic disease, panniculitis with, 429, 539
Panencephalitis, subacute sclerosing, measles and, 211
Panniculitis, **421–433**
 cutaneous polyarteritis nodosa, 424–425
 cytaphagic histiocytic, 425, 428
 eosinophilia myalgia syndrome, 423–424
 eosinophilic fascitis, 422–423
 erythema nodosum, 421–422
 idiopathic lobular, 425
 infectious, 430–431
 lipodermatosclerosis, 422
 neonatal, 429
 physical, 428–429
 polyarteritis nodosa, 424
 post-steroid, 429
 scleroderma panniculitis, 422
 superficial migratory thrombophlebitis, 424
 with α_1 -antitrypsin deficiency, 431
 with calciphylaxis, 430
 with leukemia and lymphoma, 430
 with lupus erythematosus, 430
 with nodular vasculitis, 431
 with pancreatic disease, 429, 539
 with subcutaneous sarcoidosis, 430, 436
Papanicolaou smear, in prevention of human papillomavirus, 324
Papillomavirus. *See* Human papillomavirus.
Papular acrodermatitis of childhood, hepatitis B and, 235–236
Papular purpuric “gloves and socks” syndrome, parvovirus B19 infection and, 335–336
Paraffin sections, in Mohs' micrographic surgery, for melanoma, 705
Paraneoplastic dermatoses, **523–532**
 acanthosis nigricans, 525
 acquired ichthyosis, 525–526
 Bazex's syndrome, 526
 carcinoid syndrome, 524
 clubbing, 530
 coagulopathy, 529
 Cronkhite-Canada syndrome, 530
 cryoglobulinemia, 530
 Cushing's syndrome, 524
 cutaneous amyloidosis, 528–529
 dermatomyositis. *See* Dermatomyositis.
 erythema gyratum repens, 526
 erythroderma, 529
 hypertrichosis lanuginosa acquisita, 525
 multicentric reticulohistiocytosis, 528
 necrolytic migratory erythema, 523–524
 paraneoplastic pemphigus, 526–527
 sign of Leser-Trélat, 524–525
 Sweet's syndrome. *See* Neutrophilic dermatoses.
 tripe palms, 525
Paraproteinemia, with pyoderma gangrenosum, 414
Parathyroidectomy, subtotal, for pruritus, 462
Paravaccinia, cutaneous features of, 345
Paroxetine, for pruritus, 468
Parvovirus B19 infection, **333–342**
 clinical features of, 334
 cutaneous features of, 3334–336
 diagnosis of, 337
 epidemiology of, 333
 histopathology of, 336
 in pregnancy, 337–338
 management of, 340
 pathogenesis of, 337
 populations at risk for, 337
 rheumatologic complications of, 339
 transmission of, 333
 vascular complications of, 338–339
Peginterferon alpha-2b, for mixed cryoglobulinemia, 240
Pemphigus, paraneoplastic, cutaneous features of, 526–527
Penciclovir, for herpes simplex virus, 257, 259
Periocular crow's feet, botulinum toxin for, 755–756
Perioral rhytides, botulinum toxin for, 756
Perioral skin, photodamaged, laser therapy for, 93
Periorbital melanoma, Mohs' micrographic surgery for, 706
Peripheral nervous system, in scleromyxedema, 496

Peripheral vascular disease, in cardiac disease, 504–505

Peristomal pyoderma gangrenosum, cutaneous features of, 412–413

Peutz-Jeghers syndrome, with gastrointestinal disease, 542

Photochemotherapy, for pruritus, 462, 464, 467–468

Photodamaged skin, laser therapy for. *See* Skin resurfacing.

PhotoDerm VL
for leg telangiectasias, 14, 31–33
parameters for, 5

Photodynamic therapy, in hair removal, 138

Photosensitivity disorders, with HIV infection, 203–204

Physical panniculitis, cutaneous features of, 428–429

Pigmented lesions, laser therapy for, 37–45
argon lasers in, 37
Becker's nevus, 42
blue nevi, 45
café-au-lait macules, 41–42, 171–172
complications of, 171–172
compound melanocytic nevi, 43
congenital nevi, 43–44, 172
continuous-wave lasers in, 38
ephelides, 41
junctional melanocytic nevi, 43
lentigo simplex and solar lentigo, 40
long-pulsed lasers in, 39
melasma, 42, 172
nevocellular nevi, 42–43
nevus of Ota and nevus of Ito, 44–45, 172
nevus spilus, 42
postinflammatory hyperpigmentation, 42
preoperative preparation for, 39
pulsed dye lasers in, 39
Q-switched lasers in, 38–40, 42–43, 171–172
ruby lasers in, 37
seborheic keratoses and dermatosis papulosa nigra, 40–41, 155

Pigmented pretibial papules, in diabetes mellitus, 484

Pigmented scars, revision of, lasers in, 57, 62–63

Piokiloderma of Civatte, laser therapy for, 12

Pityriasis rosea, human herpesvirus 7 and, 304–305

Planar xanthomas, in cardiac disease, 504

Plantar melanoma, surgery for, 691
Mohs' micrographic, 706

Plantar pits, in basal cell nevus syndrome, 550–551

Plasmapheresis, for pruritus, 463

Platelet-derived growth factor, for chronic wounds, 358

Platysmal rejuvenation, botulinum toxin for, 756–757

Pleconaril, for enterovirus infections, 221

Plummer-Vinson syndrome, with gastrointestinal disease, 542–543

Pneumonia, measles and, 211

Pneumonitis, interstitial, with dermatomyositis, 396–397

POCKit HSV-2 Rapid Test, for herpes simplex virus, 255

Podophyllin, for human papillomavirus, 320–321

Podophyllotoxin, for human papillomavirus, 320–321

POEMS syndrome, cutaneous features of, 555–556

Poliovirus infections. *See* Enterovirus infections.

Polyarteritis nodosa
cutaneous and renal features of, 424–425, 515
hepatitis B and, 235
with hepatitis C, 453

Polymerase chain reaction, for hepatitis C, 454

Polymerase chain reaction technique
for cytomegalovirus infections, 294–295
for enterovirus infections, 220
for herpes simplex virus, 255
for measles, 211

Polymyositis. *See* Dermatomyositis.

Porcine xenografts, for chronic wounds, 358–359

Porphyria cutanea tarda
hepatitis C and, 240–241
in dialysis patients, 517
with gastrointestinal disease, 539
with hepatitis C, 451–452
with HIV infection, 203–204

Port-wine stains, laser therapy for, 8–10
complications of, 172–173

Post-steroid panniculitis, cutaneous features of, 429

Potassium titanyl phosphate lasers. *See* KTP lasers.

Poxvirus infections, 343–346
genus Molluscipoxvirus in, 343–344
molluscum contagiosum, 343–344

genus Orthopoxvirus in, 344–345
cowpox, 345
monkeypox, 345
vaccinia, 344–345
variola, 344

genus Parapoxvirus in, 345
orf, 345
pseudocowpox, 345

genus Yatapoxvirus in, 345–346
tanapox, 345

PP65 antigenemia assay, for cytomegalovirus infections, 294

Pregnancy
herpes simplex virus in
diagnosis of, 255
management of, 258–259
recurrent, 253
herpes zoster virus in, 271
melanoma in, 693–694
parvovirus B19 infection in, 337–338
varicella in, 269

Primary effusion lymphomas, human herpesvirus 8 and, 311

Procuren, for chronic wounds, 357–358

Proliferative markers, for melanoma, 653

Propofol
for pruritus, 464
intraoperative, in laser therapy, 128

Prostaglandins, in pruritus, 460

Protease inhibitors, adverse reactions to, in HIV infection, 203

Pruritus, **459–472**
cholestasis and, 462–464
hematopoietic disease and, 464–465
hepatitis C and, 452–453
in dialysis patients, 516–517
malignancies and, 466
management of, 462–465, 467–468
mediators of itching in, 459–460
metabolic and endocrine disorders and, 465–466
neurologic disorders and, 466
pathophysiology of, 459–460
patient evaluation for, 460–461
renal disease and, 461–462

PS-341, for melanoma, 711

Pseudocowpox, cutaneous features of, 345

Pseudohypopigmentation, laser skin resurfacing and, 94

Pseudoxanthoma elasticum
cutaneous and renal features of, 514
with cardiac disease, 508
with gastrointestinal disease, 545

Psoriasis, with HIV infection, 202

Psychodermatology, nonpharmacologic managements in, **177–185**
biofeedback, 178
case reports of, 179–183
acne and excoriated acne, 181
adult eczema, 181
eczema, 180–181
pruritus, 182–183
psoriasis, 179–180
urticaria, 182
hypnosis, 178–179
psychoeducation and support, 179
psychotherapy, 179
relaxation training, 178

Psychoeducation, in psychodermatology, 179

Psychotherapy, in psychodermatology, 179

Pulmonary disease, with dermatomyositis, 395–397

Pulmonary features, of sarcoidosis, 437

Pulsed carbon dioxide lasers, in tattoo removal, 49–50

Pulsed dye lasers
for epidermal and dermal lesions, 151–152
for facial telangiectasias, 10
for hemangiomas, 6–7
for leg telangiectasias, 14, 24, 26
for pigmented lesions, 39
for poikiloderma of Civatte, 12
for port-wine stains, 8–10
for pyogenic granulomas, 13
for rosacea-associated telangiectasias and erythema, 12
for spider angiomas, 12
for striae distensae, 69
for vascular lesions
complications of, 172–173
for venous lakes, 13
in scar revision, 59–60
in skin resurfacing, 98–99

Pulsed erbium lasers, in tattoo removal, 49–50

Purpura, parvovirus B19 infection and, 334

Pustular pyoderma gangrenosum, diagnosis of, 347–348

Pustular reactions, in gastrointestinal disease, 538

Pustulosis palmoplantar, with thyroid disease, 478

Pyoderma gangrenosum. *See*
Neutrophilic dermatoses.

Pyogenic granulomas, laser therapy for, 12–13

Pyostomatitis vegetans, cutaneous features of, 413

Q

Q-switched lasers

- for pigmented lesions, 38–40, 42–43
- complications of, 171–172
- in hair removal, 137, 141
- in skin resurfacing, 99–100
- in tattoo removal, 48–49, 158
- complications of, 169–171

Quinacrine

- for cutaneous lupus erythematosus, 379
- for dermatomyositis, 400

R

Radiation therapy, for melanoma, 713–716

- palliative, 713–714
- potentially curable, 714–715

Radiofrequency devices, in laser skin resurfacing, 109

Ray amputation, for subungual melanoma, 690

Recurrent necrotic papulovesicles of face, Epstein-Barr virus infection and, 287

Regional anesthesia, in laser therapy, 123–134

- and respiratory depression, 132
- complications of, 132–133
- discharge criteria for, 133
- facial blocks in, 128–130
- complications of, 130
- inadequate, 132
- intraoperative intravenous sedation in, 128
- intraoperative patient comfort in, 130–131
- patient selection for, 124–126
- premedication for, 127–128
- preoperative evaluation for, 126
- standards for, 123–124
- technique for, 126–127

Regranex, for chronic wounds, 358

Reiter's syndrome, with HIV infection, 202

Relapsing polychondritis, with cardiac disease, 505–506

Relaxation training, in psychodermatology, 178

Renal disease, and pruritus, 461–462

Renal lesions, in tuberous sclerosis, 550

Renal transplant patients, cutaneous and renal findings in, 518–519

Repifermin, for chronic wounds, 358

Resiquimod, for herpes simplex virus, 258

Respiratory complications

- of regional anesthesia, 132
- of varicella, 269

Reticular erythematous mucinosis, cutaneous, 497–498

Reticulohistiocytosis, multicentric, cutaneous features of, 528

Retinoic acid, in skin preparation, for laser resurfacing, 116

Retinoids, for cutaneous lupus erythematosus, 380

Rheumatoid neutrophilic dermatitis, cutaneous features of, 416

Rheumatologic complications, of parvovirus B19 infection, 339

Rhinophyma, laser therapy for, 155–157

Ribavirin

- for hepatitis C, 455
- for measles, 214
- for mixed cryoglobulinemia, 240

Rifampin, for pruritus, 463

Rosacea

- erythema with, laser therapy for, 12
- telangiectasias with, laser therapy for, 12

Roseola infantum, human herpesvirus 6 and, 303

RT-PCR, for melanocytic proteins, 653

Rubella, 225–231

- clinical features of, 226
- congenital rubella syndrome, 227–230
- clinical features of, 227–228
- cutaneous features of, 228
- diagnosis of, 228–229
- differential diagnosis of, 228
- management of, 229
- mechanisms of teratogenesis in, 227
- pathology of, 229
- prevention of, 229
- differential diagnosis of, 227
- epidemiology of, 225–226
- incidence of, 225

laboratory findings in, 226
management of, 227
pathology of, 226
recent outbreaks of, 229-230
viral structure of, 225

Rubeosis faciei, in diabetes mellitus, 487

Ruby lasers
for pigmented lesions, 39
in hair removal, 139-140, 562-563
in tattoo removal, 48-49

RubyStar lasers, in hair removal, 139

S

S-100, in Mohs' micrographic surgery, for melanoma, 704

Salicylates, in sunscreens, to prevent melanoma, 602-603

Sarcoidosis, 435-447
bone marrow involvement in, 437-438
cardiac features of, 428
cutaneous features of, 435-437
diagnosis of, 440-441
disease progression in, 441
diseases associated with, 440
endocrine features of, 428
etiology of, 439-440
genetics in, 439-440
immunology in, 439
infectious and environmental factors in, 440
hepatic features of, 428
histopathology of, 440
in children, 439
incidence and epidemiology of, 439
lymphadenopathy in, 437
management of, 441-442
musculoskeletal features of, 428
neurologic features of, 428
ocular features of, 437
prognosis for, 442
pulmonary features of, 437
splenomegaly in, 437
subcutaneous, panniculitis with, 430

Scabies, with HIV infection, 201

Scars
avoidance of, in laser skin resurfacing, 118-119, 168-169
revision of
acne scars, 83-84
atrophic scars, 57, 60-62
hypertrophic scars, 56, 59-60

keloids, 56-57, 59-60
lasers in, 55-65
pigmented scars, 57, 62-63
preoperative evaluation for, 57-59
striae distensae. *See Striae distensae.*

Scleredema, cutaneous features of, 493-495

Scleroderma, with cardiac disease, 505

Scleroderma panniculitis, cutaneous features of, 422

Scleromyxedema
cutaneous, 495-497
with hyperthyroidism, 475

Sebaceous nevi, laser therapy for, 157

Seborrheic dermatitis, with HIV infection, 202

Seborrheic keratoses, laser therapy for, 40-41, 155

Sentinel lymphadenectomy, in melanoma, 684-686

Serotonin, in pruritus, 459-460

Serotonin antagonists, for pruritus, 468

Serum sickness-like syndrome, hepatitis B and, 236

Serum tumor markers, for internal malignancies, in dermatomyositis, 399

Sexual activity
and hepatitis B, 234
and hepatitis C, 238, 449-450
and herpesvirus 8, 310

Sexually transmitted diseases, prevention of, education in, 323

Shin spots, in diabetes mellitus, 484

Shulman's syndrome, cutaneous features of, 422-423

Sign of Leser-Trélat, in paraneoplastic dermatoses, 524-525

Sjögren's syndrome, with hepatitis C, 452

Skin, photodamaged, laser therapy for. *See Skin resurfacing.*

Skin cancer, laser therapy for, 155

Skin resurfacing
botulinum toxin with, 757
carbon dioxide lasers in, 77-86
collagen tightening in, 78-80
complications of, 166, 168-169
for acne scars, 83-84
for advanced damage, 82-83
for early damage, 81-82
for moderate damage, 82

indications for, 80–81
physics of, 77–78

Er:YAG lasers in, **87–96**, 108–109
complications of, 93–94, 166, 168–169
laser-tissue interaction in, 87–89
patient selection for, 89–90
results of, 90–93
with carbon dioxide laser therapy, 93

for age-related changes, 97–98

in darkly pigmented persons, lasers in, **113–121**
intraoperative period in, 117
postoperative care for, 117–119
predictable technique for, 119
preoperative preparation for, 114, 116–117
wound care in, 119–120

nonablative lasers in, **97–112**
diode lasers, 100, 106–108
erbium glass lasers, 104–105
intense pulsed light source, 101–102
Nd:YAG lasers, 105–106
pulsed dye lasers, 98–99
Q-switched Nd:YAG lasers, 99–100
radiofrequency device in, 109
short- and long-wavelength lasers, 102–103

Skin self-examination, for melanoma, 635–636

Skin tumors, malignant, human papillomavirus and, 318

“Slapped cheek” appearance, parvovirus B19 infection and, 334–335

Small-cell melanoma, of trunk and proximal extremities, 672–673

Smallpox, cutaneous features of, 344

Softlight System, in hair removal, 137–138

Solar lentigo, laser therapy for, 40

SPF system, in sunscreens, to prevent melanoma, 603

Spider angiomas, laser therapy for, 12

Spindle-shaped cell melanoma, of trunk and proximal extremities, 672

Staphylococcal infections, with HIV infection, 197

Steroids
for cutaneous lupus erythematosus, 378–379
for dermatomyositis, 400–401
for herpes zoster virus, 275–276
for infectious mononucleosis, 285
for pyoderma gangrenosum, 351–352, 415–416
for sarcoidosis, 442

Striae distensae
origin of, 67

revision of, lasers in, 57, 60, **67–76**
ablative lasers, 74
historical aspects of, 68
infrared lasers, 69
microdermabrasion with, 74–75
pulsed dye lasers, 69
topical management with, 74

Stroke, pruritus after, 466

Subacute sclerosing panencephalitis, measles and, 211

Subungual melanoma
diagnosis of, 731
surgery for, 690–691
Mohs’ micrographic, 705–706

Sun-damaged skin, melanoma of, 666–669, 673

Sunburns, and congenital melanocytic nevi, 613–614

Sunscreens
for cutaneous lupus erythematosus, 378
to prevent melanoma, **601–606**, 623
benzophenones in, 602
cinnamates in, 602
clinical studies of, 605–606
dibenzoylmethanes in, 603
historical aspects of, 601
PABA in, 602
reactions to, 604
salicylates and anthranilates in, 602–603
SPF system in, 603
vehicles for, 603–604
with immunologic damage, 604

Supra-orbital nerve blocks, in laser therapy, 129

Sweet’s syndrome. *See* Neutrophilic dermatoses.

Syphilis, with HIV infection, 198

Systemic lupus erythematosus
parvovirus B19 infection and, 339
with cardiac disease, 505
with hepatitis C, 453

Systemic sclerosis
cutaneous and renal features of, 515
parvovirus B19 infection and, 339

T

Tacrolimus, for pyoderma gangrenosum, 353

Tanapox, cutaneous features of, 345

Tattoo removal, lasers in, 45–50, 158
anesthesia in, 50
complications of, 45, 48, 169–171

pulsed carbon dioxide and erbium lasers in, 49–50

Q-switched alexandrite lasers in, 49

Q-switched Nd:YAG lasers in, 49

Q-switched ruby lasers in, 48–49

technique for, 50

wound care in, 50

Taxanes, for melanoma, 709

Telangiectasias

- facial, laser therapy for, 10–11
- complications of, 173
- gingival, in dermatomyositis, 394
- hereditary hemorrhagic, with gastrointestinal disease, 544
- leg. *See* Leg telangiectasias.
- rosacea-associated, laser therapy for, 12

Teledermatology, to diagnose melanoma, 736–737

Temozolomide, for melanoma, 711

Tendinous xanthomas, in cardiac disease, 504

Thalidomide

- for cutaneous lupus erythematosus, 379
- for pruritus, 462

Thick skin, in diabetes mellitus, 486–0487

Thrombophlebitis, superficial migratory, cutaneous features of, 424

Thyroglossal dust cysts, cutaneous features of, 473–474

Thyroid disease, **473–481**

- adult hypothyroidism, 477
- alopecia area with, 477
- anemia with, 477
- bullous disorders with, 477–478
- congenital hypothyroidism, 476–477
- connective tissue diseases with, 478
- endocrinopathies with, 478
- Graves' disease, 475–476
- hyperthyroidism, 474–475
- hypothyroidism, 476
- McCune-Albright syndrome with, 479
- pustulosis palmoplantar with, 478
- Sweet's syndrome with, 478–479
- thyroglossal duct cysts, 473–474
- urticaria with, 478
- vitiligo with, 478

TNM system, to classify melanoma, 647–649

Total body photography, in melanoma surveillance, 622

Transcutaneous electrical nerve stimulation, for pruritus, 468

Traumatic tattoos, laser therapy for, 170

Treponema pallidum, with HIV infection, 198

Tretinoin

- in skin preparation, for laser resurfacing, 116
- with laser therapy, for striae distensae, 74

Trichloroacetic acid, for human papillomavirus, 320

Trichophyton rubrum, with HIV infection, 199

Trimethoprim-sulfamethoxazole, adverse reactions to, in HIV infection, 203

Tripe palms, cutaneous features of, 525

Trunk, melanoma of, 664–666, 672–673

Tuberculosis, with HIV infection, 197–198

Tuberous sclerosis, cutaneous and renal features of, 513–514, 549–550

Tuberous xanthomas, in cardiac disease, 504

Tumid cutaneous lupus erythematosus, diagnosis of, 377

Tumor necrosis factor

- in cutaneous lupus erythematosus, 374
- in dermatomyositis, 402
- in limb perfusion, for recurrent melanoma, 688–689

U

Ulceration, to classify melanoma, 648

Ulcerative colitis

- cutaneous features of, 533
- with pyoderma gangrenosum, 414

Ulcerative pyoderma gangrenosum, diagnosis of, 347

Ulcers, genital, infectious mononucleosis and, 284–285

Ultra-long pulsed dye lasers

- for facial telangiectasias, 10–11
- for leg telangiectasias, 14
- parameters for, 4–5

Ultraviolet light

- avoidance of, for dermatomyositis, 400
- sensitivity to, dysplastic nevi and, 619

Urticaria

- with hepatitis C, 452
- with thyroid disease, 478

V

Vaccines

- for congenital rubella syndrome, 229
- for hepatitis B, 237
- for herpes simplex virus, 260–261
- for human papillomavirus, 322–324
- for measles, 213–214
- for melanoma, **717–725**
 - adjuvant, 721
 - choice of, 724
 - clinical trials of, results of, 721–723
 - nonpurified, 719–720
 - partially purified, 720–721
 - patient information on, 723
 - patient selection for, 723
 - purified, 720
 - rationale for, 717
 - requirements for, 717–719
- for vaccinia, 344–345
- for varicella, 276–277

Vaccinia, cutaneous features of, 344–345

Valacyclovir

- for herpes simplex virus, 256–258
- for herpes zoster virus, 275

Varicella-zoster virus infection, **267–282**

- herpes zoster virus in, 270–273
 - acute, 270–271
 - chronic, 271–272
 - clinical features of, 272
 - complications of, 272–273
 - in immunocompromised patients, 271
 - in pregnancy and neonatal period, 271
 - management of, 275–276
 - failure of, 276
 - pathogenesis of, 270
 - varicella in, 267–270
 - clinical features of, 268–269
 - complications of, 269–270
 - diagnosis of, 273–275
 - in immunocompromised patients, 268–269
 - in pregnancy and neonatal period, 269
 - management of, 273–275
 - pathogenesis of, 267–268
 - prevention of, 276–277
 - postexposure, 277–278
 - with HIV infection, 194–195

Varicella-zoster virus-specific immune globulin, for varicella-zoster virus infection, 277–278

Variola, cutaneous features of, 344

Vascular complications, of parvovirus B19 infection, 338–339

Vascular invasion, by melanoma, 652–653, 674

Vascular lesions, laser therapy for, **1–8**

- alexandrite lasers in, 5–6
- argon-pumped tunable dye lasers in, 2, 11
- cherry angiomas, 13–14
- complications of, 172–173
- continuous-wave argon lasers in, 1–2, 6–7, 10
- copper vapor and copper bromide lasers in, 2, 11–12
- diode lasers in, 3, 6
- facial telangiectasias, 10–11, 173
- hemangiomas, 6–8, 173
- intense pulsed light source in, 5, 14
- krypton lasers in, 2
- KTP lasers in, 2
- leg telangiectasias. *See* Leg telangiectasias.
- long-pulsed dye lasers in, 4, 14
- Nd:YAG lasers in, 8
- poikiloderma of Civatte, 12
- port-wine stains, 8–10, 172–173
- pulsed dye lasers in, 3–4, 6–10, 12–14
- pyogenic granulomas, 12–13
- rosacea-associated telangiectasias and erythema, 12
- spider angiomas, 12
- ultra-long pulsed dye lasers in, 4–5, 10–11, 14
- venous lakes, 13

Versapulse lasers in, 6

VCAM-1, in dermatomyositis, 398

Vegetative pyoderma gangrenosum, diagnosis of, 348–349

Venous lakes, laser therapy for, 13

Vermilionectomy, lasers in, 154

Verrucae, laser therapy for, 150–152

Versapulse lasers, parameters for, 6

Vertical transmission

- of hepatitis B, 234
- of hepatitis C, 238

Vinblastine, for melanoma, 709

Vinca alkaloids, for melanoma, 709

Viral cultures

- of cytomegalovirus infections, 294
- of enterovirus infections, 220
- of herpes simplex virus, 254–255
- of herpes zoster virus, 273
- of pyoderma gangrenosum, 349

Viral hepatitis, **233–247**

- hepatitis A, 233

hepatitis B, 233–237
and papular acrodermatitis of childhood, 235–236
and polyarteritis nodosa, 235
and serum sickness–like syndrome, 236
clinical features of, 234–235
epidemiology of, 234
management of, 237
prevention of, 236–237
risk factors for, 234
virology of, 233–234

hepatitis C, 237–242
and lichen planus, 241–242
and mixed cryoglobulinemia, 239–240
and porphyria cutanea tarda, 240–241
clinical features of, 238–239
epidemiology of, 237
risk factors for, 237–238
virology of, 237

Viral infections
and scleredema, 493
with HIV infection, 193–197

Vitamin A, for measles, 214

Vitiligo
with hepatitis C, 453
with thyroid disease, 478

Vitrix, for chronic wounds, 362

von Recklinghausen's disease, cutaneous and renal features of, 513

Vulvar pyoderma gangrenosum, cutaneous features of, 413

W

Weber-Christian disease, cutaneous features of, 425

Wegener's granulomatosis, cutaneous and renal features of, 515–516

Werner syndrome, with cardiac disease, 508–509

Wound care, in pyoderma gangrenosum, 350–351

Wounds, chronic. *See Chronic wounds.*

X

Xanthomas, in cardiac disease, 504

Xenografts, for chronic wounds, 358–359

Xeroderma pigmentosum, cutaneous features of, 552–553

Xerosis, with HIV infection, 201–202

Y

Yellow skin, in diabetes mellitus, 487

Z

Zidovudine, adverse reactions to, in HIV infection, 203

Zoster sine herpete, clinical features of, 272

